Kazutaka Kido

USPTO Granted Patents = 8 (Patent Applications = 1)

CIPO Patents = 1

EPO Patents = 2 (Patent Applications = 2)

Average Co-Inventor Count = 4.2

ph-index = 3

Forward Citations = 24(Granted Patents)

Location History:

Ikoma, JP (2009 - 2018)
Osaka, JP (2014 - 2022)

Company Filing History:

6 out of 281

Santen Pharmaceutical Co., Ltd.

Santen Pharmaceuticalco., Ltd.

patents

where one patent can have more than one assignee

Years Active: 2009-2022

Loading Chart...

8 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11419880 - Ursodeoxycholic acid-containing agent for treating or preventing presbyopia (2022-08-23),

2. 9999594 - Therapeutic or preventive agent for meibomian gland dysfunction or meibomian gland blockage (2018-06-19),

3. 9539204 - Therapeutic or preventive agent for meibomian gland dysfunction or meibomian gland blockage (2017-01-10),

4. 8816092 - Indazole derivative or salt thereof and production intermediate thereof, and antioxidant using same, and use of indazole derivative or salt thereof (2014-08-26),

5. 8232308 - Methods for treating a disease in which Rho kinase is involved (2012-07-31),

6. 8227480 - Indazole derivative having spiro ring structure in side chain (2012-07-24),

7. 7855222 - Methods for treating a disease in which Rho kinase is involved (2010-12-21),

8. 7563906 - Indazole derivatives (2009-07-21),

Title: Kazutaka Kido: Innovator in Eye Health

Introduction

Kazutaka Kido is a prominent inventor based in Ikoma, Japan, known for his significant contributions to the field of eye health. With a total of eight patents to his name, Kido has focused on developing innovative treatments for various eye conditions.

Latest Patents

One of Kido's latest patents is an agent for treating or preventing presbyopia, which includes ursodeoxycholic acid or its derivatives as active ingredients. This invention aims to address eye diseases such as presbyopia effectively. Another notable patent is a therapeutic agent for meibomian gland dysfunction or blockage, which utilizes clarithromycin as an active ingredient. This invention is designed to be administered in the form of eye drops or ointments, providing a new medicinal use for this well-known antibiotic.

Career Highlights

Throughout his career, Kido has worked with reputable companies, including Santen Pharmaceutical Co., Ltd. and Ube Industries, Inc. His work in these organizations has allowed him to advance his research and contribute to the development of effective eye care solutions.

Collaborations

Kido has collaborated with notable professionals in the field, including Masahiko Hagihara and Ken-ichi Komori. These collaborations have further enriched his research and innovation efforts.

Conclusion

Kazutaka Kido's work in developing treatments for eye health showcases his dedication to improving patient care through innovation. His patents reflect a commitment to addressing significant health challenges in the field of ophthalmology.

This text is generated by artificial intelligence and may not be accurate.